Skip to main content
Erschienen in: Journal of Cancer Survivorship 2/2015

01.06.2015

An algorithm to identify the development of lymphedema after breast cancer treatment

verfasst von: Tina W. F. Yen, Purushuttom W. Laud, Rodney A. Sparapani, Jianing Li, Ann B. Nattinger

Erschienen in: Journal of Cancer Survivorship | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Large, population-based studies are needed to better understand lymphedema, a major source of morbidity among breast cancer survivors. One challenge is identifying lymphedema in a consistent fashion. We sought to develop and validate an algorithm using Medicare claims to identify lymphedema after breast cancer surgery.

Methods

From a population-based cohort of 2,597 elderly (65+) women who underwent incident breast cancer surgery in 2003 and completed annual telephone surveys through 2008, two algorithms were developed using Medicare claims from half of the cohort and validated in the remaining half. A lymphedema-positive case was defined by patient report.

Results

A simple two ICD-9 code algorithm had 69 % sensitivity, 96 % specificity, positive predictive value >75 % if prevalence of lymphedema is >16 %, negative predictive value >90 %, and area under receiver operating characteristic curve (AUC) of 0.82 (95 % CI 0.80–0.85). A more sophisticated, multi-step algorithm utilizing diagnostic and treatment codes, logistic regression methods, and a reclassification step performed similarly to the two-code algorithm.

Conclusions

Given the similar performance of the two validated algorithms, the ease of implementing the simple algorithm and the fact that the simple algorithm does not include treatment codes, we recommend that this two-code algorithm be validated in and applied to other population-based breast cancer cohorts.

Implications for Cancer Survivors

This validated lymphedema algorithm will facilitate the conduct of large, population-based studies in key areas (incidence rates, risk factors, prevention measures, treatment, and cost/economic analyses) that are critical to advancing our understanding and management of this challenging and debilitating chronic disease.
Literatur
1.
Zurück zum Zitat Efron B. How biased is the apparent error rate of a prediction rule? J Am Stat Assoc. 1986;81:461–70.CrossRef Efron B. How biased is the apparent error rate of a prediction rule? J Am Stat Assoc. 1986;81:461–70.CrossRef
2.
Zurück zum Zitat Cooper GS, Virnig B, Klabunde CN, Schussler N, Freeman J, Warren JL. Use of SEER-Medicare data for measuring cancer surgery. Med Care. 2002;40(8 Suppl):IV-43-8.PubMed Cooper GS, Virnig B, Klabunde CN, Schussler N, Freeman J, Warren JL. Use of SEER-Medicare data for measuring cancer surgery. Med Care. 2002;40(8 Suppl):IV-43-8.PubMed
3.
Zurück zum Zitat McClish DK, Penberthy L, Whittemore M, Newschaffer C, Woolard D, Desch CE, et al. Ability of Medicare claims data and cancer registries to identify cancer cases and treatment. Am J Epidemiol. 1997;145:227–33.CrossRefPubMed McClish DK, Penberthy L, Whittemore M, Newschaffer C, Woolard D, Desch CE, et al. Ability of Medicare claims data and cancer registries to identify cancer cases and treatment. Am J Epidemiol. 1997;145:227–33.CrossRefPubMed
6.
Zurück zum Zitat Nattinger AB, Laud PW, Bajorunaite R, Sparapani RA, Freeman JL. An algorithm for the use of Medicare claims data to identify women with incident breast cancer. Health Serv Res. 2004;39:1733–49.PubMedCentralCrossRefPubMed Nattinger AB, Laud PW, Bajorunaite R, Sparapani RA, Freeman JL. An algorithm for the use of Medicare claims data to identify women with incident breast cancer. Health Serv Res. 2004;39:1733–49.PubMedCentralCrossRefPubMed
7.
Zurück zum Zitat Freeman JL, Zhang D, Freeman DH, Goodwin JS. An approach to identifying incident breast cancer cases using Medicare claims data. J Clin Epidemiol. 2000;53:605–14.CrossRefPubMed Freeman JL, Zhang D, Freeman DH, Goodwin JS. An approach to identifying incident breast cancer cases using Medicare claims data. J Clin Epidemiol. 2000;53:605–14.CrossRefPubMed
8.
Zurück zum Zitat Warren JL, Feuer E, Potosky AL, Riley GF, Lynch CF. Use of Medicare hospital and physician data to assess breast cancer incidence. Med Care. 1999;37:445–56.CrossRefPubMed Warren JL, Feuer E, Potosky AL, Riley GF, Lynch CF. Use of Medicare hospital and physician data to assess breast cancer incidence. Med Care. 1999;37:445–56.CrossRefPubMed
9.
Zurück zum Zitat Ramsey SD, Scoggins JF, Blough DK, McDermott CL, Reyes CM. Sensitivity of administrative claims to identify incident cases of lung cancer: a comparison of 3 health plans. J Manag Care Pharm. 2009;15:659–68.PubMed Ramsey SD, Scoggins JF, Blough DK, McDermott CL, Reyes CM. Sensitivity of administrative claims to identify incident cases of lung cancer: a comparison of 3 health plans. J Manag Care Pharm. 2009;15:659–68.PubMed
10.
11.
Zurück zum Zitat Hassett MJ, Ritzwoller DP, Taback N, Carroll N, Cronin AM, Ting GV, et al. Validating billing/encounter codes as indicators of lung, colorectal, breast, and prostate cancer recurrence using 2 large contemporary cohorts. Med Care. 2012. doi:10.1097/MLR.0b013e318277eb6f. Hassett MJ, Ritzwoller DP, Taback N, Carroll N, Cronin AM, Ting GV, et al. Validating billing/encounter codes as indicators of lung, colorectal, breast, and prostate cancer recurrence using 2 large contemporary cohorts. Med Care. 2012. doi:10.​1097/​MLR.​0b013e318277eb6f​.
12.
13.
Zurück zum Zitat Lamont EB, Herndon 2nd JE, Weeks JC, Henderson IC, Earle CC, Schilsky RL, et al. Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344). J Natl Cancer Inst. 2006;98:1335–8. doi:10.1093/jnci/djj363.PubMedCentralCrossRefPubMed Lamont EB, Herndon 2nd JE, Weeks JC, Henderson IC, Earle CC, Schilsky RL, et al. Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344). J Natl Cancer Inst. 2006;98:1335–8. doi:10.​1093/​jnci/​djj363.PubMedCentralCrossRefPubMed
14.
Zurück zum Zitat McClish D, Penberthy L, Pugh A. Using Medicare claims to identify second primary cancers and recurrences in order to supplement a cancer registry. J Clin Epidemiol. 2003;56:760–7.CrossRefPubMed McClish D, Penberthy L, Pugh A. Using Medicare claims to identify second primary cancers and recurrences in order to supplement a cancer registry. J Clin Epidemiol. 2003;56:760–7.CrossRefPubMed
15.
Zurück zum Zitat Earle CC, Nattinger AB, Potosky AL, Lang K, Mallick R, Berger M, et al. Identifying cancer relapse using SEER-Medicare data. Med Care. 2002;40(8 Suppl):IV-75-81.PubMed Earle CC, Nattinger AB, Potosky AL, Lang K, Mallick R, Berger M, et al. Identifying cancer relapse using SEER-Medicare data. Med Care. 2002;40(8 Suppl):IV-75-81.PubMed
18.
Zurück zum Zitat Petrek JA, Pressman PI, Smith RA. Lymphedema: current issues in research and management. CA Cancer J Clin. 2000;50:292–307. quiz 8–11.CrossRefPubMed Petrek JA, Pressman PI, Smith RA. Lymphedema: current issues in research and management. CA Cancer J Clin. 2000;50:292–307. quiz 8–11.CrossRefPubMed
19.
Zurück zum Zitat Sparaco A, Fentiman IS. 9. Arm lymphoedema following breast cancer treatment. Int J Clin Pract. 2002;56:107–10.PubMed Sparaco A, Fentiman IS. 9. Arm lymphoedema following breast cancer treatment. Int J Clin Pract. 2002;56:107–10.PubMed
20.
Zurück zum Zitat Hayes SC, Johansson K, Stout NL, Prosnitz R, Armer JM, Gabram S, et al. Upper-body morbidity after breast cancer: incidence and evidence for evaluation, prevention, and management within a prospective surveillance model of care. Cancer. 2012;118(8 Suppl):2237–49. doi:10.1002/cncr.27467.CrossRefPubMed Hayes SC, Johansson K, Stout NL, Prosnitz R, Armer JM, Gabram S, et al. Upper-body morbidity after breast cancer: incidence and evidence for evaluation, prevention, and management within a prospective surveillance model of care. Cancer. 2012;118(8 Suppl):2237–49. doi:10.​1002/​cncr.​27467.CrossRefPubMed
21.
Zurück zum Zitat Maunsell E, Brisson J, Deschenes L. Arm problems and psychological distress after surgery for breast cancer. Can J Surg. 1993;36:315–20.PubMed Maunsell E, Brisson J, Deschenes L. Arm problems and psychological distress after surgery for breast cancer. Can J Surg. 1993;36:315–20.PubMed
23.
Zurück zum Zitat Shih YC, Xu Y, Cormier JN, Giordano S, Ridner SH, Buchholz TA, et al. Incidence, treatment costs, and complications of lymphedema after breast cancer among women of working age: a 2-year follow-up study. J Clin Oncol. 2009;27:2007–14. doi:10.1200/JCO.2008.18.3517.CrossRefPubMed Shih YC, Xu Y, Cormier JN, Giordano S, Ridner SH, Buchholz TA, et al. Incidence, treatment costs, and complications of lymphedema after breast cancer among women of working age: a 2-year follow-up study. J Clin Oncol. 2009;27:2007–14. doi:10.​1200/​JCO.​2008.​18.​3517.CrossRefPubMed
25.
Zurück zum Zitat Erickson VS, Pearson ML, Ganz PA, Adams J, Kahn KL. Arm edema in breast cancer patients. J Natl Cancer Inst. 2001;93:96–111.CrossRefPubMed Erickson VS, Pearson ML, Ganz PA, Adams J, Kahn KL. Arm edema in breast cancer patients. J Natl Cancer Inst. 2001;93:96–111.CrossRefPubMed
26.
Zurück zum Zitat Petrek JA, Heelan MC. Incidence of breast carcinoma-related lymphedema. Cancer. 1998;83(12 Suppl American):2776–81.CrossRefPubMed Petrek JA, Heelan MC. Incidence of breast carcinoma-related lymphedema. Cancer. 1998;83(12 Suppl American):2776–81.CrossRefPubMed
27.
Zurück zum Zitat Armer JM, Stewart BR. Post-breast cancer lymphedema: incidence increases from 12 to 30 to 60 months. Lymphology. 2010;43:118–27.PubMedCentralPubMed Armer JM, Stewart BR. Post-breast cancer lymphedema: incidence increases from 12 to 30 to 60 months. Lymphology. 2010;43:118–27.PubMedCentralPubMed
28.
Zurück zum Zitat McLaughlin SA. Lymphedema: separating fact from fiction. Oncology. 2012;26:242–9.PubMed McLaughlin SA. Lymphedema: separating fact from fiction. Oncology. 2012;26:242–9.PubMed
29.
31.
Zurück zum Zitat From cancer patient to cancer survivor: lost in translation. 1 ed. Washington, D.C.: National Academies Press; 2005. From cancer patient to cancer survivor: lost in translation. 1 ed. Washington, D.C.: National Academies Press; 2005.
35.
Zurück zum Zitat ICD-9 CM International classification of diseases, 9th revision. Millenium edition. 2008. Los Angeles: Practice Management Information Corporation; 2007. ICD-9 CM International classification of diseases, 9th revision. Millenium edition. 2008. Los Angeles: Practice Management Information Corporation; 2007.
36.
Zurück zum Zitat Current Procedural Terminology: CPT 2004. Chicago: American Medical Association; 2003. Current Procedural Terminology: CPT 2004. Chicago: American Medical Association; 2003.
37.
Zurück zum Zitat HCPCS Health Care Financing Administration Common Procedure Coding System. National Level II Medicare Codes. Millennium edition. 2008. Los Angeles: Practice Management Information Corporation; 2007. HCPCS Health Care Financing Administration Common Procedure Coding System. National Level II Medicare Codes. Millennium edition. 2008. Los Angeles: Practice Management Information Corporation; 2007.
38.
Zurück zum Zitat Kwan W, Jackson J, Weir LM, Dingee C, McGregor G, Olivotto IA. Chronic arm morbidity after curative breast cancer treatment: prevalence and impact on quality of life. J Clin Oncol. 2002;20:4242–8.CrossRefPubMed Kwan W, Jackson J, Weir LM, Dingee C, McGregor G, Olivotto IA. Chronic arm morbidity after curative breast cancer treatment: prevalence and impact on quality of life. J Clin Oncol. 2002;20:4242–8.CrossRefPubMed
42.
Zurück zum Zitat International Society of Lymphology. The diagnosis and treatment of peripheral lymphedema. 2009 Consensus Document of the International Society of Lymphology. Lymphology. 2009;42:51–60. International Society of Lymphology. The diagnosis and treatment of peripheral lymphedema. 2009 Consensus Document of the International Society of Lymphology. Lymphology. 2009;42:51–60.
43.
Metadaten
Titel
An algorithm to identify the development of lymphedema after breast cancer treatment
verfasst von
Tina W. F. Yen
Purushuttom W. Laud
Rodney A. Sparapani
Jianing Li
Ann B. Nattinger
Publikationsdatum
01.06.2015
Verlag
Springer US
Erschienen in
Journal of Cancer Survivorship / Ausgabe 2/2015
Print ISSN: 1932-2259
Elektronische ISSN: 1932-2267
DOI
https://doi.org/10.1007/s11764-014-0393-z

Weitere Artikel der Ausgabe 2/2015

Journal of Cancer Survivorship 2/2015 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.